Archives: BioMedWire

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company whose lead drug candidate Berubicin has yielded promising results in the treatment of glioblastoma multiforme (“GBM”), has made equally significant strides with its second drug candidate, WP1244. Still currently in development, preclinical work for WP1244 is expected to continue during 2021 and 2022. “WP1244 is a DNA-binding agent believed to be 500-times more potent than daunorubicin in inhibiting tumor cell proliferation,” reads a recent article. “The current target indication for WP1244 includes brain cancers, pancreatic cancers, ovarian cancers and lymphoma. Preclinical studies show high uptake in the brain with antitumor activity.” On the other hand, Berubicin, “a novel anthracycline that is the first anthracycline to cross the blood-brain barrier and is designed to concentrate in tumorous tissue within the brain, is currently entering a potentially pivotal Phase 2 study for GBM.”

To view the full article, visit https://ibn.fm/31RYO

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Healthy Extracts (OTCQB: HYEX) recently released its full-year 2020 report. In addition to achieving a 71% jump in its revenue on the back of a plant-based industry boom, the company announced it was at an advanced stage of clinical testing that would culminate in the release of a new product in Q2 2021. The proprietary Fuel4Thought Brain Booster product will add to Health Extracts’ portfolio, which has increased thanks to acquisitions. An article on the developments reads, “Healthy Extracts acquired BergaMet NA in 2019, engaged in selling and distributing a full line of proprietary formulations derived from the rare Citrus Bergamot Superfruit(TM) (‘bergamot’) native to Southern Italy.” The company also acquired Ultimate Brain Nutrients, which “develops unique, plant-based superior proprietary neuro-brain solutions that enhance the brain’s overall health.”

To view the full article, visit https://ibn.fm/nVWiY

About Healthy Extracts Inc.

Healthy Extracts, through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, visit www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A recent study conducted by University of Nottingham researchers suggests that the environment in which men inhabit could impact their reproductive health. The study, which was reported in “Scientific Reports,” examined the impact of geographical location on chemicals discovered in testes of dogs. Some of these chemicals have been found to influence reproductive health.

The study centered on dogs because they are common pets and are usually exposed to the same chemicals used in the house as their owners…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

A large-scale study conducted by researchers from UC San Francisco and UC Davis Health has found that Down syndrome is a high-risk factor for childhood leukemia. The study, which evaluated the leukemia risk in children suffering from Down syndrome, was reported in the “Journal of Pediatrics.” It found a strong link between acute myeloid leukemia, which is a type of blood cancer, and Down syndrome.

Down syndrome, among the most prevalent genetic conditions in Canada and the United States, affects roughly 6,000 infants born annually in the two countries. That equates to roughly one in every 750 babies…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment (“UME,” “UMEBSNI”) is well-positioned to help speed up economic recovery with its FDA-approved COVID-19 rapid test kits. This comes as governments in different parts of the world have expressed interest in rapid testing, citing health and economic benefits. An article on the matter reads, “New York City is wasting no time to leverage the power of this low-cost, high impact option as the city has announced the launch of its Forward Rapid-Test Program. The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The UK government is also looking at introducing rapid lateral-flow testing to open the parts of the economy that could not open last year, including night clubs and theaters.” United Medical’s rapid test “is designed to detect coronavirus antibodies in the bloodstream of infected individuals within 10 minutes, which helps position the company at the core of the strategy to bring both economy and society back to normal.”

To view the full article, visit https://ibn.fm/1AI3w

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track to launch its niclosamide programs in the clinic, noting that just this month the company announced the initiation of RESERVOIR, its Phase 2 clinical trial of niclosamide for the treatment of COVID-19-related gastrointestinal infections; the company also established an agreement with PPD Inc. (“PPD”), a leading clinical research organization, to manage the upcoming Phase 1b/2a ICI-AC trial, planned for Q2 2021. Sapirstein also shared that the company is continuing the development of MS1819 as a potential treatment for exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”) and is anticipating to release topline data from its Phase 2 combination therapy trial using MS1819 in combination with pancreatic enzyme replacement therapy (“PERT”), which is the current standard of care. The letter noted that the company continues to believe that MS1819 could replace PERT as the gold standard treatment for EPI in patients with CF and chronic pancreatitis (“CP”). The letter also provided further information about MS1819, the company’s most advanced clinical asset. The letter also provided detailed information about the two niclosamide clinical trials scheduled for 2021 and offered a summary of financial information for Q1 2021. “These are exciting times for AzurRx, and we anticipate several catalysts on the horizon,” said AzurRx BioPharma chair, president and CEO James Sapirstein in the letter. “I look forward to working with my management team and fellow board members to execute a business and clinical strategy that has the potential to transform AzurRx and generate substantial returns for our shareholders. We will continue to pursue our efforts to drive long-term shareholder value by delivering safe and effective GI therapies for patients who need them the most, raising our global visibility and broadening our shareholder base. We look forward to continuing what has been a productive 2021.”

To view the full letter, visit https://ibn.fm/cbezg

About AzurRx BioPharma Inc. 

AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, is set to launch a solution for improving detection of the virus responsible for the worldwide pandemic. The company recently announced European regulatory approval of its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system. Known as “Covid-ID Lab,” the system is a commercial in-vitro diagnostic device (CE-IVD) designed to help industry professionals and government agencies screen for the virus. XPhyto’s exclusive German diagnostics partner, 3a-diagnostics GmbH, developed Covid-ID Lab to provide rapid, accurate and portable testing capabilities, granting it marketability as a product with increased convenience and decreased operating costs. “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” said XPhyto CEO and Director Hugh Rogers of the innovative solution. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”

To view the full article, visit https://ibn.fm/zVfe8

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, is fulfilling a growing need for improved neurological monitoring that is cost efficient, disposable and portable. When combating a highly contagious disease, disposable technology helps to ensure that the virus is not spread through equipment. Brain Scientific’s disposable EEG caps are designed for single use and also assist in shortening person-to-person contact due to ease of placement, decreasing transmission between staff and patient. “As health-care facilities and frontline workers move quickly to address COVID symptoms and provide effective treatment, disposable devices offer a solution to rapidly and safely assess neurological changes in these patients,” stated Brain Scientific co-founder and executive chairman Boris Goldstien in a recent article. “Disposable EEG headsets are a cost-effective, readily-available solution that can be adopted for widespread use in these facilities during the current pandemic and moving forward to help health care workers gain a quick, reliable picture of a patient’s condition and receive treatment insights.”

To view the full article, visit https://ibn.fm/pZwVA

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has hailed its first product, the i/Blue(TM) Imaging System, as a breakthrough technology that will advance the accuracy and efficiency of bladder cancer detection and removal, thus helping it capture some market share. The global endoscopy market is valued at $46 billion, of which Imagin is positioned to target $400 million with its bladder cancer detection product. An article detailing this reads, “The company’s patented ultrasensitive imaging product based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for treatment is bladder cancer.” According to the article, this product provides several advantages, such as improved visualization during minimally invasive surgery (“MIS”). With the i/Blue Imaging System, “the surgeon can simultaneously view both white and blue light video streams in a single frame and in real-time on the surgical monitor, without having to toggle between the two images.”

To view the full article, visit https://ibn.fm/mhBPd

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A recent study conducted by a faculty member from the University of Georgia, in partnership with a team of researchers from the University of Southern California, has found that the daily consumption of beverages sweetened with sugar during adolescence damages performance on a memory and learning task during adulthood. The group of researchers demonstrated that changes in the bacteria found in the gut could be the key to the memory impairment caused by sugar.

High-sugar diets have also been associated with health effects such as heart disease and obesity as well as impaired…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by Williams. The paper, which was published in “Proceedings of the National Academy of Science, USA,” was titled “Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.” The research identified the collagen VI pathway, which 180 Life Sciences is now pursuing in preclinical studies. The findings reported in the paper were compiled as a result of Williams’s work as a member of Professor Jagdeep Nanchahal’s research team; Nanchahal is chairman of 180 Life Sciences’ Clinical Advisory Board. The announcement noted that Dr. Thomas Layton, another member of Nanchahal’s research team in Oxford, was named as a joint  recipient of the International Dupuytren Award in both 2020 and 2019. Nanchahal and his clinical research team received the 2019 award for the publication of the phase 2a clinical trial data. “This pivotal research for which Dr. Williams has received this award, was published in a high-impact journal and provides insight into Collagen VI pathways to identify novel potential therapeutic targets for fibrotic diseases,” said 180 Life Sciences CEO James Woody in the press release. “This research from our team, led by Professor Jagdeep Nanchahal, is the foundation of our program to develop new treatments for fibrosis.”

To view the full press release, visit https://ibn.fm/1LF2E

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in America and is board-certified in cardiovascular disease, nuclear cardiology and internal and integrative holistic medicine. “We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ chairman and chief executive officer. “As a global medical leader in comprehensive and holistic approaches to cardiovascular disease and sleep disorders, she will be a valuable addition to our growing organization. Her wealth of experience and credibility as an award-winning physician and researcher will help inform other physicians about our breakthrough diagnostic and treatment technologies.”

To view the full press release, visit https://ibn.fm/JYD5M

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 15,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced that it will host a private event featuring Dr. Shelley Rankin, a professor of microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). Attended by a select group of veterinarians, the private seminar will feature data compiled by Rankin based on her studies evaluating the use of LexaGene’s MiQLab to detect Staphylococcus in specimens gathered from canine skin infections. The event will also include information regarding the use of molecular diagnostics in veterinary medicine as well as analytical and clinical data generated using LexaGene’s MiQLab system. The studies performed by Rankin and LexaGene were designed to analyze and evaluate the performance of LexaGene’s MiQLab to detect common bacterial pathogens encountered in veterinary medicine. To conduct the analytical studies and clinical urine study, MiQLabs were equipped with LexaGene’s MiQLab(TM) Bacterial and AMR Test. The test is designed to screen for 7 common bacterial pathogens and 13 different antimicrobial resistance factors. Rankin noted that LexaGene’s MiQLab returns a molecular analysis on specimens in a fraction of the time it takes for culture to return results, enabling veterinarians to quickly identify infection and offer pet owners evidence-based treatment options. “Our goal has always been to have the MiQLab generate high-quality data inside veterinary clinics where veterinarians can use this data to guide treatment decisions,” said LexaGene CEO and founder Jack Regan in the press release. “These data prove we have achieved this goal. Our sales team will be using these data to secure sales in the veterinary market, which has relatively few options for quality in-hospital pathogen testing.”

To view the full press release, visit https://ibn.fm/4JOmQ

About LexaGene Holdings Inc. 

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research organization will manage the clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, or FW-420 (“CRO”). The trial is designed to evaluate proprietary formulations of micronized niclosamide for grade 1 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors (“ICIs”). This is the second clinical trial involving niclosamide that the CRO will manage for AzurRx. As previously announced, PPD is also managing AzurRx’s phase 2 clinical trial to investigate niclosamide as a treatment for COVID-19-related gastrointestinal infections; that trial is planned for Q2 2021. “The goal of our FW-420 clinical program is to develop a safe, effective, and non-systemic treatment for immune checkpoint inhibitor-associated colitis, and we are excited to once again partner with PPD to begin the preparations for our Phase 1b/2a clinical trial,” said AzurRx BioPharma president and CEO James Sapirstein in the press release. “The development of immune checkpoint inhibitors has marked a major advance in cancer therapeutics, but the drugs can induce a serious inflammation of the bowels, which if left unchecked, can prove life-threatening and force patients to halt treatment. There are currently no treatments available for grade 1 colitis resulting from the use of ICIs. We believe an oral, non-absorbed treatment, such as FW-420, could prevent the condition from progressing and enable patients to continue their treatment regimen uninterrupted. We hope to rapidly advance the FW-420 program with the support of PPD.” To view the full press release, visit https://ibn.fm/k4JfZ About AzurRx BioPharma Inc. AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com. NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

A new study conducted by researchers from the University of Minnesota Medical School and their colleagues has found three phenotypes of the novel coronavirus, which demonstrate distinct characteristics as well as different clinical outcomes, complications and comorbidities in patient populations. The three COVID-19 phenotypes were discussed in detail in the researchers’ study, which was reported in the open-access “PLOS ONE” journal.

The coronavirus has infected more than 18 million individuals as well as led to the death of more than 700,000 people across the globe. The disease’s presentation varies considerably, which suggests that not only do distinct clinical phenotypes exist, but those phenotypes may also respond…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

A group of researchers from the Feinberg School of Medicine at Northwestern University has discovered additional evidence of cognitive dysfunction in many coronavirus patients who were not hospitalized after contracting the infection. The group’s findings were reported in the “Annals of Clinical and Translational Neurology” journal.

In the study, the researchers looked into medical data of nonhospitalized coronavirus patients from 21 different states who were experiencing long-term symptoms…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, today announced that it will partner with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2021. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands of the InvestorBrandNetwork, will also serve as an official media partner for DGE’s upcoming events. InvestorBrandNetwork and BioMedWire will provide dedicated virtual coverage, including a syndicated article on each event with full dissemination to IBN’s 5000+ strategic syndication partners, social media coverage of the events through IBN’s accounts that have collectively amassed more than 2 million likes and followers across a variety of platforms, as well as featured placement on IBN and BMW event pages. “We are delighted to be collaborating with InvestorBrandNetwork and BioMedWire,” said DGE’s Marketing Manager, Elizabeth Stanislaw, MBA. “IBN’s widespread syndication network and dozens of trusted brands will deliver incredible visibility for our sponsors. Moreover, their multifaceted approach will complement our existing strategy to reach larger audiences.”

To view the full press release, visit https://ibn.fm/I08Ja

About Dynamic Global Events (“DGE”)

DGE has established itself as a leader within the life sciences industry by providing business-to-business (“B2B”) events that service the dynamic informational and networking needs of the pharmaceutical, biotechnology, medical device, health care, and allied industries. Founded in 2017, DGE has rapidly made a strong impression with its diverse portfolio of live, virtual and hybrid events spanning a wide range of topics, including: Advancing Women’s Leadership (“AWLC”), Virtual Clinical Trials (“VCT”), Digital Marketing for Life Sciences, Medical Affairs Leadership (“MALF”) and Business Development & Licensing (“BD&L”). For more information about Dynamic Global Events, visit www.DGEvents.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Bioscience technology accelerator XPhyto Therapeutics Corp. recently announced it had placed its first order for its Covid-ID Lab rapid, portable virus test from its German development partner
• XPhyto received approval for the test kit last month from European regulators with oversight of in vitro diagnostic device (CE-IVD) use certification and the internationally agreed-on ISO 13485 medical product quality standards
• The Covid-ID Lab is designed to help beleaguered industries and government regulators quickly screen for the COVID-19 virus at point-of-care sites, and the company expects to begin sales and distribution in April
• XPhyto has just completed a rebranding effort that includes the launch of a new website
• The company expects to begin launching other bacteria and virus diagnostic products later this year

With confidence in the world’s mounting recovery from the COVID-19 pandemic growing this year, bioscience industry holding company XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is stepping up its efforts to produce and ultimately commercialize next-generation diagnostic products and new active pharmaceutical ingredients, particularly in regard to the pandemic response.

XPhyto has placed its first order for the company’s Covid-ID Lab product from its exclusive diagnostic development partner, Germany’s 3a-diagnostics GmbH, as announced in a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Distribution of neurologists across the U.S. is uneven with 20 states experiencing neurology deserts
• Brain Scientific has developed tools that help providers in neurology deserts provide access to neurological care
• With explosion of telemedicine services and increased integration of advanced practice providers, neurologists’ shortage may improve

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is directly tackling the shortage of neurologists in the United States with cutting-edge technologies. By creating cost-efficient, disposable and portable EEGs, BRSF makes neurology care more accessible without putting excess strain on the already overextended neurologist labor pool.

Between 2001 and 2016, the American Academy of Neurology (“AAN”) reported that out-of-pocket costs shot up substantially for privately insured patients. In addition, the distribution of neurologists across the U.S. is uneven, with patients in rural areas less likely to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. The data were presented at the 2021 American Association of Cancer Research (“AACR”) annual meeting. “We are pleased to have these positive data that provide further support for the therapeutic potential of REQORSA in combination with immunotherapies and targeted therapies in NSCLC presented before an audience of the world’s leading cancer researchers. These data are particularly encouraging as we look to initiate our upcoming combination Acclaim-1 and Acclaim-2 clinical trials of REQORSA in NSCLC,” said Rodney Varner, president and chief executive officer of Genprex. “We know that many patients inevitably develop resistance to immune checkpoint blockade therapy or EGFR-TKI therapy. These data show that REQORSA in combination with immunotherapies and targeted therapies may provide enhanced efficacy in NSCLC that has become resistant to these regimens, offering hope to a large patient population who currently has limited treatment options.”

To view the full press release, visit https://ibn.fm/xMOps

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Researchers from Harvard, MIT, the Ragon Institute of MGH, Brigham and Women’s Hospital and Massachusetts General Hospital recently conducted a study that discovered that the new mRNA coronavirus vaccines were highly efficacious in producing antibodies against the SARS-CoV-2 virus in lactating and pregnant women. The researchers also showed that the vaccines offered protective immunity to newborns through the placenta and breast milk.

Their findings were reported in the “American Journal of Obstetrics and Gynecology” and observed 131 women, 16 of whom weren’t pregnant, 31 who were lactating and 84 who were pregnant, all of reproductive age. All the study participants received one of the two new mRNA vaccines: Moderna or Pfizer/BioNTech. The antibodies were found to be equal in all three groups. Additionally, any side effects observed after the vaccines…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Every product features three parts: dosing device, formulation accessory and mobile app
• HIPPA-compliant cloud collects data along each step that is essential in tailoring personalized treatment plan
• RYAH offers multi-product ecosystem that provides remote-health solutions in patient treatment

RYAH Group a digital health-care analytics and technology company, has developed an ecosystem of IoT products in its mission to advance the world’s transition to remote-health solutions and data analytics in patient treatments (https://ibn.fm/1wvz4). Every product features three parts: the device, the formulation accessory (QR labeled product) and the mobile application. These parts work together to control the dosing while also capturing important data that can lead to breakthroughs in plant-based medicine.

Every RYAH dose-measuring product has an innovative dose-control solution. Using QR-labeled products, patients can track what they use and evaluate what dosing parameters work best for each product. The QR labeling allows for advanced session tracking and journaling and is designed to ensure safety. Patients can then control and rate the effectiveness of each session on…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Predictive Oncology (NASDAQ: POAI) has set sights on other cancers after completing its data generation milestones in a collaborative study with UPMC-Magee Women Hospital. With the comprehensive genomic and transcriptomic sequencing of patient samples now complete, thanks to the study, and patient outcome data having been obtained from UPMC-Magee, “these data will now be used to drive POAI’s AI models of ovarian cancer and their internal ovarian cancer drug re-purposing project.” This is according to an article detailing the matter. “‘The successful generation of high-quality genomic and transcriptomic data from archived materials at Helomics, together with the gathering of historical outcome data from our collaborator UPMC-Magee, demonstrates that we can leverage Helomics’ unique asset and deliver significant value,’ said Predictive Oncology CEO Dr. Carl Schwartz. ‘Furthermore, this project is a template we can use to partner with other health care institutions and expand our AI-driven clinical models to other cancers.’”

To view the full article, visit https://ibn.fm/fMpmj

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins, including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Bioscience technology accelerator XPhyto Therapeutics Corp. is working with development partner 3a-diagnostics GmbH to roll out its pandemic-related virus diagnostic tool for the European market planned in April
• The test solution, dubbed “Covid-ID Lab,” received European regulatory approval last month
• XPhyto’s product is designed to be portable and rapid in its response time to help decrease testing operation costs and increase convenience of use
• News reports about the COVID-19 pandemic reflect a growing optimism that vaccine, mask and distancing protocols may be helping to drive down infection rates, although the reports note the virus continues to have a deadly effect on many people
• Government and industry leaders have been looking for accurate and rapid diagnostic tools that may make it easier for travel operations and other businesses to resume robust activity despite the continued presence of the infectious virus

Vaccine distribution to millions of people and reports of declining rates of COVID-19 infection are generating optimism in the United States that the health crisis and its economic devastation are beginning to retreat before a modern medical technology assault, even as health officials continue to issue warnings that the deadly virus and its variants are still very active (https://ibn.fm/cl8Vk).

Bioscience technology accelerator XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) is now ready to launch its own solution for improving detection of the virus responsible for the worldwide pandemic. The company announced on March 18 that European regulatory officials have approved its point-of-care SARS-CoV-2 (COVID-19) RT-PCR test system, known more simply as…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers from the University of Iowa recently examined the link between the risk of death and dining out and came to the conclusion that eating out too often was linked to an increased risk of all-cause death. The findings were reported in the “Journal of the Academy of Nutrition and Dietetics.”

Eating out is a popular activity globally, and while not much research has been done into its link with health outcomes, the conclusion warrants…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) continues to aggressively pursue FDA approval for its lead drug candidate, Berubicin. The novel candidate is the first anthracycline that appears to be able to cross the blood-brain barrier to combat tumors — stepping up its cancer-fighting potential. Berubicin was the subject of a Phase 1 safety trial conducted by Reata Pharmaceuticals approximately 15 years ago. One of the trial participants has remained alive and cancer-free as of the most recent evaluation late last year, while two other patients in the small study saw reductions of greater than 25% (one being an 80% reduction) in the size of their tumors. CNS Pharmaceuticals is advancing the development of Berubicin for potential commercialization in treating glioblastoma multiforme (“GBM”), a type of brain cancer that is nearly 100% fatal in one year after diagnosis. The company has progressed its plans for a world-spanning Phase 2 trial comparing Berubicin’s response to the effectiveness of established chemotherapy drug lomustine in 243 GBM patients. “The participants for the Phase 2 study will be adult GBM patients with recurrent disease (Grade IV, as measured by the World Health Organization) after the failure of standard first-line therapy,” reads a recent article on the new trial. “The primary endpoint of the study is to demonstrate overall survival, ‘a rigorous endpoint the FDA recognizes when a statistically significant improvement can be shown relative to a randomized control arm,’ the company states.”

To view the full article, visit https://ibn.fm/AEyIb

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a solution set to lower the cost of treating bladder cancer and also help hospitals save money. As a result, Imagin will create a win-win situation for every party involved. The i/Blue(TM) Imaging System, Imagin’s proprietary solution, achieves this in two ways. “By displaying the blue light image that shows the highlighted cancer cells alongside the white light image that shows the full landscape of the bladder, the i/Blue Imaging System will provide surgeons with improved visualization to locate and resect tumors. The overall result is a reduction in the cost of treatment as detailed in a report by Urology Times.” The article detailing these developments continues, “Further, the i/Blue Imaging System’s camera head can be attached to any cystoscope, meaning that a hospital need not buy new cystoscopes to use the blue light fluorescent technology.”

To view the full article, visit https://ibn.fm/eG3En

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• BRSF is creating mobile, easy-to-use electroencephalogram (“EEG”) devices that enhance research integrity
• There is an increasing desire to understand the brain’s capabilities and harness them for healing
• Brain Scientific provides a cost-efficient, pre-gelled, disposable and wireless solution that provides the same signal quality as the traditional wired EEG

A growing consumer market for brain-computer interface (“BCI”) technology has some researchers worried about the quality of the data being collected. Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has developed wireless, portable, easy-to-use electroencephalogram (“EEG”) devices that do not compromise research integrity.

Data collected from consumer-centric, low-cost BCIs are typically not as efficient or as pristine as that retrieved from research-grade conventional wired EEGs. However, the sudden growth of this market, which reached 1.2 billion in 2019, is largely due to a rise in neuroprosthetic conditions, a growing geriatric population, and a desire to communicate and facilitate movement in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Glioblastoma Multiforme (often known simply as GBM) is a fatal, incurable class of brain cancers that usually leaves patients only about 15 months to live once they are diagnosed
• A recent study by the Washington University School of Medicine found that the length of survivability appeared to improve when the standard chemotherapy regimen was given in the morning instead of the evening
• Brain cancer drug developer CNS Pharmaceuticals is also working on a solution to improve the quality of GBM care, seeing hope in its lead drug candidate, Berubicin, which showed promise in a small Phase 1 trial nearly 15 years ago
• One patient from that Phase 1 trial was still alive and cancer-free as of the most recent assessment in November
• CNS expects to begin a larger, multi-center potentially pivotal trial imminently (as well as collaborating on two Polish trials conducted by sublicensee partner WPD Pharmaceuticals), comparing Berubicin’s performance to the chemotherapy drug lomustine in hundreds of patients at nearly 60 oncology centers around the world

A new study recently completed by the Washington University School of Medicine in St. Louis has found that glioblastoma (“GBM”) brain cancer patients receiving the current chemotherapy standard of care had longer survivability rates if they switched from receiving treatments in the evening to receiving the treatments in the morning — encouraging news for patients with the incurable illness, as well as for neuro-oncology researchers attempting to develop improved treatments, including biopharmaceutical company CNS Pharmaceuticals (NASDAQ: CNSP).

“In my lab, we were studying daily rhythms in astrocytes, a cell type found in the healthy brain. We discovered some cellular events in healthy cells varied with time of day,” professor of biology Erik D. Herzog, PhD, stated in a Science Daily report on the study Herzog co-authored with professor of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Healthy Extracts (OTCQB: HYEX) is engaged in proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. HYEX recently announced promising clinical study results for two of its subsidiary companies’ leading products: BergaMet North America’s HERHEART(TM) and Ultimate Brain Nutrients’ Fuel4Thought(TM) Brain Booster. “HERHEART(TM) is an exclusive natural supplement that is scientifically formulated specifically for women to support cardiovascular health, including perimenopausal symptoms. The study was conducted in 35 postmenopausal women with sexual dysfunction at the University Magna Graecia of Caranzaro in Italy. Results indicated that patients who were administered HERHEART(TM) reported a 40% decrease in mood swings and 60% reduction in hot flashes, along with a 45% increase in energy and a 40% to 70% increase in desire and arousal. The supplement was also shown to have beneficial effects in fat metabolizing, lower cholesterol levels and anti-inflammatory action,” reads a recent article discussing the products. “Shortly after releasing results for HERHEART(TM), the company’s UBN subsidiary released its study of Fuel4Thought(TM) Brain Booster, showing impressive results in brain activation, sports vision, hand-to-eye coordination, and auditory reaction time. The results were presented by Dr. Neil Wolkadoff and Dr. Gerald Haase at the 2020 meeting of the American College of Sports Medicine. The prospective, randomized, double-blind, and placebo-controlled trial was completed at the Colorado Center for Health and Sport Science.”

To view the full article, visit https://ibn.fm/aIyjX

About Healthy Extracts Inc.

Healthy Extracts, through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, visit www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A group of scientists from Monash University and King’s College London has developed a database of information that may help researchers find the link between type 2 diabetes and the coronavirus. The group designed the database for the following reasons: first, the increasing evidence that suggests that the coronavirus can actually cause individuals to become diabetic, and second, when compared to the general population, individuals who have type 2 diabetes are more likely to experience serious coronavirus symptoms and to die from the disease. Type 2 diabetes is a chronic condition that impacts the way the body processes blood sugar.

The database, dubbed the COVIDIAB registry, has been created to assist medical researchers to understand the association between diabetes and the coronavirus. The data that was gathered from patients included whether the diagnoses were new onset. The researchers suggest that the amount of data will increase as researchers learn more about the effect of the coronavirus…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• 90% of the cystoscopies performed on bladder cancer patients use white light, which cannot always detect cancer margins or tumors that lie flat against the bladder wall. The American Urology Association recommends blue light for cystoscopic procedures involving bladder cancer.
• Imagin Medical’s i/Blue Imaging System(TM) provides the simultaneous, side-by-side display of white light and blue light images, making it easier to visualize cancer margins and flat tumors, potentially resulting in lower recurrence rates
• The company is has transitioned to the manufacturing stage of the i/Blue System with their contract manufacturer, Lighthouse Imaging
• Bladder cancer is the sixth most prevalent cancer in the United States, with approximately 81,400 new cases in 2020 and approximately 17,980 deaths in 2020

Surgical imaging company, Imagin Medical (CSE: IME) (OTCQB: IMEXF), is on the innovative edge of visualizing bladder cancer, aiming to overcome the challenges associated with current imaging techniques. The conventional treatment for bladder cancer is white light cystoscopy that allows doctors to insert a cystoscope equipped with a lens through the urethra to illuminate and examine the outer wall of the bladder.

Cystoscopies may be performed for the following…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Healthy Extracts Inc. recently declared its 2020 Q4 results, with revenue growth at 71% over the previous year
• The company’s 2021 strategy “Live Life Young Again” aligns with its plant-based product range and its overall confidence for 2021
• Results of the clinical studies of the Fuel4Thought Brain Booster product were published in the renowned World Journal of Advanced Research and Reviews

Healthy Extracts (OTCQB: HYEX), is engaged in the research, development, and sale of natural plant-based products that concentrate on nerve and heart health. The company’s growth and expansion are evident in the company’s robust 2020 Q4 results. Their latest financial report highlights the revenue increase of 71% at $1,276,559 compared to 2019 revenues of $748,377. The plant-based food industry is expected to reach a value of $74.2 billion in 2027, guided by a CAGR of 11.9% from 2020 to 2027 (https://ibn.fm/qeyzR).

Duke Pitts, president of Healthy Extracts Inc., stated that the 2020 results reflected the upward momentum of the company. The company recently changed its name from Grey Cloak Tech Inc. to Healthy Extracts, Inc., better aligned with the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

A recent study led by researchers from the University of Minnesota, both from the College of Science and Engineering and the Medical School, demonstrated how heart valves that were developed in the lab and infixed in young lambs for a year could grow in the recipient. When tested in the same lamb model, the researchers found that the valves demonstrated decreased calcification and better flow of blood function in comparison with valves derived from animals.

If those results are confirmed in humans, these heart valves may help prevent multiple valve replacement surgeries for children born annually with heart defects. Additionally, these valves can be stored for roughly half a year, which means that they could offer…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that it has initiated its Phase 2 RESERVOIR clinical trial of a proprietary oral formulation of micronized niclosamide (“FW-1022”) for the treatment of COVID-19-related gastrointestinal (GI) infections. Patient enrollment is expected to begin in April 2021 with topline data anticipated in the first quarter of 2022. “Initiation of the Phase 2 clinical trial of FW-1022 for the treatment of COVID-19 GI infection, or the RESERVOIR trial, is a significant milestone for AzurRx and an important advance in the ongoing battle to help those infected by COVID-19 to overcome the often long-lasting effects of the virus,” said James Sapirstein, chairman, CEO and president of AzurRx BioPharma. “COVID-19 is a pernicious disease and, despite the ongoing vaccine rollout, one that continues to impact hundreds of thousands of people worldwide every day in addition to the millions who have already been infected. For many, the after-effects of COVID-19 can be as bad as the disease itself, and this includes a growing number who experience severe GI complications due to what many believe is the ability of SARS-CoV-2 to hide in reservoirs within the GI tract. We believe micronized oral niclosamide has the potential to target SARS-CoV-2 directly in the gut and, doing so, become an important addition to the armamentarium of therapeutics that will unfortunately be required by many who contract COVID-19.”

To view the full press release, visit https://ibn.fm/kh4lH

About AzurRx BioPharma Inc.

AzurRx BioPharma is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor; FW-1022 for COVID-19 gastrointestinal infections and FW-420 for grade 1 immune checkpoint inhibitor-associated colitis and diarrhea in oncology patients. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Researchers struggle to understand the immediate effects of COVID, with no clear census on the long-term neurological impact
• COVID-19 has shown itself to be unique in how it interacts with the brain
• Brain e-tattoos implanted in forehead will be next wave of innovation for neurology

Brain Scientific (OTCQB: BRSF) is meeting the growing need for improved brain monitoring with cost-efficient, disposable, and portable cutting-edge technology. This last year has seen an increased demand for disposable neurological technology accessible to all, adaptable for widespread use, and that provides quick, reliable information on the patient’s condition.

As the pandemic winds down, thanks to dedicated medical workers, social-distancing, mask-wearing and new vaccines, there are still many questions that need to be…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

According to analysts from Jefferies, two decades from now, there may be no smokers in the market. Tobacco firms and governments happen to be on the same side in this shift, especially now that more countries are adopting smoke-free targets and companies are advocating for smokers to use alternative products such as oral nicotine and vaping.

In a note, one of the analysts, Owen Bennett, stated that as tobacco ambitions and regulators align, no smokers in a generation may become a reality, adding…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Rapid testing is cheaper, faster than PCR testing; some fear test sensitivity is too low
• Recent studies show that test sensitivity is secondary to frequency and turnaround time for effective COVID-19 screening
• UME widespread rapid testing gains momentum as safe, reliable and more cost-effective alternative

As a trusted supplier of testing kits, United Medical Equipment (“UME”) is eager to provide assistance and support in the fight against COVID-19 as as research indicates effectiveness of rapid testing for COVID-19 screening (https://ibn.fm/eZoVI). Governments have invested significant resources in scaling up testing capacity as a response to the pandemic outbreak. Because SARS-CoV-2 can spread from individuals with presymptomatic, symptomatic and asymptomatic infections, the containment of the virus and reopening of societies may… Read More>> NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment (“UME,” “UMEBSNI”), a company offering rapid COVID-19 testing kits, looks positioned to benefit from the high demand for its products. The demand arises from expert recommendations that identifying those infected through rapid testing could help curb the virus and prevent the emergence of new variants. An article about these developments reads, “‘Testing is actually more important now than it was eight months ago because of the high contagiousness rate of these new variants,’ Mara Aspinall, a professor of health practice at Arizona State University, said in a recent interview for NPR. ‘It is critical to stop these new strains right in their tracks. And the only way to do that is to test.’ Identifying those infected through country wide rapid testing could be vital for curbing the virus and preventing new variants from emerging. The country reportedly needs tens of millions of tests every day to avoid another surge, while it buys time to get enough people vaccinated.”

To view the full article, visit https://ibn.fm/Lr4iY

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Current POAI Chairman J. Melville (“Mel”) Engle has been appointed to CEO position
• Engle has held executive positions throughout his career at leading pharma and medical device companies, including Dey L.P. (a subsidiary of Merck KGaA), Allergan, Anika Therapeutics and Thermogenesis
• During his time at Merck’s Dey L.P., Engle transitioned the company from generics to branded products and grew sales from $250 million to $600 million

The world today uses big data for all sorts of predictions, especially consumer behavior. One day, though, big data and technology could prove even more valuable as the catalyst to flip the healthcare script from one that is almost exclusively reactive, to a proactive one that foretells disease at best and eliminates trial and error in therapy decisions after a disease presents at worst. That’s the hope of Predictive Oncology (NASDAQ: POAI), a company using an extensive dataset collected over the last 15 years to better inform individualized cancer therapies today as it advances development of its predictive tumor profiling technology rooted in its artificial intelligence (“AI”) platform.

The company recently named J. Melville (“Mel”) Engle as chief executive officer. Engle has been a director at POAI since October 2016 and has sat as chairman of the board since January 2020. He will take on the top executive role and continue to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, has announced that its COO and Executive VP, Michael Redman, will present at the annual Cell & Gene Meeting on the Mediterranean. The event is slated to take place virtually from April 6-9, 2021, with company presentations available for on-demand viewing throughout the entirety of the conference. Organized by the Alliance for Regenerative Medicine, the four-day virtual conference will feature more than 80 dedicated company presentations by leading public and private companies, highlighting recent technical and clinical achievements in the areas of cell therapy, gene therapy, gene editing, tissue engineering, and broader regenerative medicine technologies. The event also includes more than 50 panelists and featured speakers taking part in 13 in-depth sessions covering all aspects of cell and gene therapy commercialization.

To view the full press release, visit https://ibn.fm/cVxFX

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared key takeaways from its topline results on its Phase 2b OPTION 2 clinical trial. The trial studied AzurRx’s drug candidate MS1819 in the treatment of cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). MS1819 is a recombinant lipase enzyme for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The trial results were shared during a March 31, 2021, conference call hosted by AzurRx president, CEO and chair James Sapirstein and AzurRx chief medical officer Dr. James Pennington. Included in the announcements were the company’s plans to develop an optimized formulation of MS1819 for ongoing clinical investigation. “The best word to describe the OPTION 2 topline results is mixed,” said AzurRx president, CEO and chair James Sapirstein in the press release. “MS1819 demonstrated itself to be safe and well-tolerated and data from OPTION 2, and other Phase 2 clinical trials, clearly demonstrate drug activity. However, OPTION 2 did not consistently meet the primary efficacy endpoint. Some patients were able to achieve CFA at levels beyond what is required to demonstrate non-inferiority with PERT therapies, but the majority did not, and as such, we did not meet our trial goal. . . . To that end, we are planning to pursue a new formulation for MS1819, this one a capsule filled with acid-resistant granules, or microbeads, similar to what is used in CREON(R), ZENPEP(R) and other PERT therapies. Such a capsule would dissolve in the stomach, disperse the beads, and then pass through to the small intestine where the beads would break down and release the lipase enzyme so that it thoroughly mixes with food as it is being digested. We are moving full force with developing the optimal formulation technology for MS1819.”

To view the full press release, visit https://ibn.fm/iDkA2

About AzurRx BioPharma Inc. 

AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A pilot study that was conducted recently by Northwestern Medicine has discovered that when a female athlete experiences a concussion when the hormone progesterone is at its highest during her menstrual cycle phase, she experiences less stress. Experiencing less stress is a recovery marker while feeling more stress is among the symptoms of a concussion.

The study, which was reported in the “Journal of Neurotrauma,” also found that the reason for the neural protection was the increase…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• New York City ramps up rapid testing efforts, opens 11 rapid-testing sites; others to follow
• Mayor notes that low-cost, rapid-testing made available to public is key to accelerating economy’s re-opening
• UME offers rapid -testing kits, provides products and services essential for curbing pandemic and jumpstarting economic recovery

United Medical Equipment Business Solutions Network (“UME”), a trusted supplier of COVID-19 antigen and antibody testing kits, is offering a key product that could impede the spread of the virus and speed up economic recovery. A top U.S. testing official announced a scale-up in the country’s diagnostic efforts, touting both health and economic benefits of rapid testing outside the lab. New York City is wasting no time to leverage the power of this low-cost, high-impact option as the city has announced the launch of its Forward Rapid-Test Program (https://ibn.fm/c1SAa).

The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The city has initially announced that 11 sites will open with the capacity to conduct more than 5,000 tests every day. Additional locations are planned across the city and other parts of the state in…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, has provided a corporate update in a shareholder letter from LexaGene CEO and founder Dr. Jack Regan. In the letter, Regan reported that the company had crossed a major milestone by securing a sales contract in both the drug and vaccine manufacturing market and in the veterinary medicine space; both sales were the result of successful technology demonstrations, the letter noted. The company has also focused on ensuring consistency in microfluidic operations across MiQLab(TM) systems, Regan observed, noting that expectations have now been met and the company is ramping up manufacturing. The letter also reported that LexaGene has built 20 MiQLab systems, with plans and parts in hand or on order for another 70 systems if needed to meet demand. The company is also investing resources in supporting the veterinary diagnostics market and evaluating the open-access marke, specifically contract drug manufacturing organizations (“CDMOs”), pharmaceutical companies and cosmetic manufacturers. “Due to our increased confidence in the stability of our manufacturing process and very positive interactions with key opinion leaders in veterinary medicine and CDMOs, over the next six weeks, we anticipate hiring four to six sales representatives to improve our coverage across the United States,” said LexaGene CEO and founder Dr. Jack Regan in the letter. “In support of our sales staff, our marketing team continues to generate collateral needed to help the sales team educate prospective customers. . . . Over the last three months, we have made substantial progress on FDA requirements for software and hardware testing, which are pre-requisites to complete the COVID-19 EUA application. On the biology side, our preliminary limit-of-detection (LoD) tests for SARS-CoV-2 suggest the MiQLab sensitivity is competitive with the best point-of-care molecular systems on the market today. We plan to continue the additional work needed for the COVID-19 EUA application as soon as we complete the validation work necessary for the MiQLab’s software, signal processing algorithm, and microfluidic scripts.”

To view the full press release, visit https://ibn.fm/bWchu

About LexaGene Holdings Inc. 

LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for onsite rapid testing in veterinary diagnostics and food safety, and for use in open-access markets such as clinical research, agricultural testing and biodefense. End users simply need to collect a sample, load the sample onto the instrument with a sample preparation cartridge, enter the sample ID and press go. The MiQLab system delivers excellent sensitivity, specificity and breadth of detection, and can return results in approximately one hour. The unique open-access feature is designed for custom testing so that end users can load their own real-time PCR assays onto the instrument to target any genetic target of interest. For more information about the company, visit www.LexaGene.com.

NOTE TO INVESTORS: The latest news and updates relating to LXXGF are available in the company’s newsroom at https://ibn.fm/LXXGF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

As the coronavirus vaccines become more accessible in the United States, two infectious disease experts from Georgetown University Medical Center assert that protecting oneself against the presymptomatic and asymptomatic spread of the SARS-CoV-2 virus, which causes the coronavirus, is the key to ending the pandemic.

Both from the Georgetown University Center for Global Health Science and Security, Saskia V. Popescu and Angela L. Rasmussen published their research on the transmission of SARS-CoV-2 without symptoms in the “Science” journal on March 19. The researchers both claim that the symptomless transmission…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

BioSig Technologies (NASDAQ: BSGM), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the U.S. Patent Office had allowed a utility patent covering its PURE EP(TM) noise-filtering technology. According to the update, the recently allowed patent application number 17/082,564, entitled, “SYSTEMS AND METHODS FOR PERFORMING ELECTROPHYSIOLOGY (‘EP’) SIGNAL PROCESSING ” was filed on October 28, 2020. “We are pleased to announce this newest patent allowance, which demonstrates the clinical significance of our PURE EP(TM) System in filtering noise from complex cardiac signals in the electrophysiological setting,” said Kenneth L. Londoner, chairman and CEO of BioSig Technologies. “The industry reports consistently indicate that inability to detect small intracardiac signals and difficulties to record high-quality signals account for some of the main factors that interfere with effective cardiac ablations. We believe that we have the leading patent-protected solution for ensuring signal clarity that is paramount to the success of cardiac ablations for all types of cardiac arrhythmias.”

To view the full press release, visit https://ibn.fm/xJbQ8

About BioSig Technologies

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals. The company’s first product, PURE EP(TM) System, is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (“EP”) procedures in an EP laboratory. For more information about the company, visit  www.BioSig.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Research conducted recently has discovered that individuals who are hospitalized with coronavirus infections have an increased risk of stroke in comparison with individuals who have similar infectious illnesses such as sepsis and influenza from previous studies.

The study found that patients who suffered from ischemic stroke were more likely to suffer from atrial fibrillations, type 2 diabetes, and high blood pressure, as well as come from the Black race, be male and be older. This was in comparison with other coronavirus patients. These findings were presented…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that preclinical data of its TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies, as well as in combination with targeted therapies to overcome resistance to osimertinib, for the treatment of non-small cell lung cancer (“NSCLC”), will be featured in two presentations at the upcoming annual meeting of the American Association for Cancer Research (“AACR 21”). The event is slated to take place virtually from April 9-14, 2021. “We look forward to the presentation of these data that highlight the potential of TUSC2 immunogene therapy to enhance chemo-immune combination treatments and overcome resistance to osimertinib in lung cancer, to an audience of the world’s leading cancer researchers,” said Rodney Varner, president and chief executive officer of Genprex. “As lung cancer is the leading cause of cancer deaths worldwide, we remain keenly focused on initiating our Acclaim-1 and Acclaim-2 clinical trials to evaluate REQORSA, our proprietary TUSC2 immunogene therapy, in non-small cell lung cancer.”

To view the full press release, visit https://ibn.fm/ajAYO

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has announced a new service called MyoCorrect. The exclusive training provides therapists with access to orofacial myofunctional therapy (“OMT”) via telemedicine technology using the company’s Vivos System. Vivos anticipates this new service will provide increased revenue through With this new training, Vivos expects to see additional revenue through increased cases and fees. The company expects its MyoCorrect service will become an effective treatment of OSA, thereby giving Vivos an additional competitive advantage in the OSA treatment marketplace. “The launch of this new service is an important step for Vivos as we continue to offer what we believe are the best therapeutic options available for patients who suffer from sleep disordered breathing and the most prevalent forms of obstructive sleep apnea,” said Vivos chair and VEO Kirk Huntsman in the press release. “We believe we will be able to leverage our current infrastructure and growing dentist network for rapid deployment and adoption of the MyoCorrect OMT therapy. As Vivos-trained dentists come to experience the ways in which OMT can enhance their Vivos System case outcomes, we expect the adoption rate of MyoCorrect as an integral part of the Vivos System to rise. As that happens, the revenue contributions of MyoCorrect to Vivos in the form of increased Vivos System sales as well as fees charged for the OMT service could be significant.”

To view the full press release, visit https://ibn.fm/i39O8

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in more than 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology (NASDAQ: POAI) is a knowledge-driven company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery. While the pharmaceutical industry has historically invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics, the use of genomics alone has proven disappointing. Predictive Oncology is confident that a multi-omic approach offers a much greater ability for success. The company is a leader in this area where few comprehensive, multi-omic datasets exist, especially in cancer, and such data is difficult to quickly access, as well as costly and time-consuming to collect. “The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer,” reads a recent article discussing the company’s positioning. “The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes.”

To view the full article, visit https://ibn.fm/1bKIk

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Healthy Extracts Inc. recently declared its 2020 Q4 results showing an exponential revenue increase of 71% from last year
• The company’s proprietary Fuel4Thought(TM) Brain Booster product is undergoing clinical testing, and is slated for release in Q2
• Healthy Extracts, Inc.(TM) officially changed its name from Grey Cloak Tech Inc. on March 1, 2020

Healthy Extracts (OTCQB: HYEX), is a leading researcher and manufacturer of plant-based formulations whose objective is to offer a better lifestyle through superior heart and brain health technology. The company is focused on strengthening and expanding its market reach through its science-based wholly-owned subsidiaries BergaMet North America (BergaMet NA) and Ultimate Brain Nutrients (“UBN”).

In a recent announcement by Healthy Extracts, the company revealed its year-end financial reports for the year ending Dec. 31, 2020. Financial highlights of the report include revenue increases of 71% to $1,276,559 compared to…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Healthtech Solutions’ (OTC: HLTT) subsidiary, Medi-Scan Inc., was featured in a recent BioWorld(TM) article titled, “Medi-Scan’s digital tool converts ultrasound images to 3D at the point of care.” The piece discusses Medi-Scan’s cloud-based software that has the capability to rapidly (in less than two minutes) convert the data on ultrasound analog 2D grayscale images into a digital 3D high-definition (“HD”) format. The company’s efforts currently focus on the heart and lungs, as it aims to provide quick, point-of-service evaluation and triaging of patients with heart disease and other conditions, including those suffering from COVID-19. Medi-Scan’s machine learning-based solution provides clinicians with a portable, hand-held device that connects to their smartphone through a mobile app that includes multiple reporting features and a full, built-in EMR with telehealth capability. “When you’re delivering a 3D image of whatever region you’re focused on, you can do a scan not moving the patient in the ER,” David Rubin, CEO of Medi-Scan, stated in the article. As the patient’s condition progresses over time, “you can walk over with a portable, wireless device and scan the patient and get insights into whether the patient is getting better or worse.”

To view the full article, visit https://ibn.fm/HajIg

Healthtech Solutions Inc.

Healthtech Solutions is the parent company of Medi-Scan Inc. and RevHeart Inc. Through its subsidiary, Medi-Scan, the company offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com.

NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A study conducted recently discovered that nearly 35% of Americans who have a history with cancer have a higher chance of contracting cardiovascular ailments in the next 10 years, as compared to roughly 23% of Americans who do not have cancer.

Researchers from The Ohio State University discovered that the average approximated 10-year risk for an individual who survived cancer was nearly 8%, in comparison with individuals who did not have a cancer history, which was found to be 5%. This was based off of a risk calculator…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment (“UME,” “UMEBSNI”) was featured in the The Bell2Bell Podcast, a part of InvestorBrandNetwork’s (“IBN”) sustained effort to provide specialized content distribution via widespread syndication channels. UME’s President, Jason Pratt, and VP of Sales, Brian Gartland, joined the latest episode to discuss United Medical Equipment’s trusted-provider business model. “Every day, 10,000 people turn 65 in the United States. Having a home health background, I saw the need to have trusted resources for seniors and their families,” Pratt said in the interview. “A lot of home health care companies are only worried about their census, not about providing good care. Even recently there have been a lot of fraudulent deals in the PPE world because of COVID-19. We wanted to structure a trusted business model – a company with a good reputation that provides resources to seniors. We also have medication management technology that allows seniors, their caregivers and their families to download our app and manage their medication. In addition, we provide up to an 80% discount on all medication from 70,000 pharmacies around the United States.”

To view the full press release, visit https://ibn.fm/6qJr6

About United Medical Equipment Business Solutions Network Inc.

United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific (OTCQB: BRSF), with its low-cost, portable, wireless and easy-to-use electroencephalogram (“EEG”) devices, the NeuroCap(TM) and NeuroEEG(TM), has overcome the barriers preventing the use of EEGs in emergency settings. This means that patients and emergency departments can more readily realize numerous EEG benefits. An EEG can make the distinction between dementia and delirium, adequately determine the severity of a mild traumatic brain injury (“mTBI”), as well as identify nontraumatic causes of neurologic dysfunction such as syncope and vertigo. In contrast, head CTs or MRIs are not equipped to effectively perform any of these tasks, yet they are widely used. “So why are EEGs not used more often?” asks an article discussing the matter. “The size of traditional EEG systems, lack of portability and inadequate numbers of trained personnel are key factors contributing to the underuse of the EEG in emergency medicine. Brain Scientific has overcome these barriers with two separate devices that make it possible for EEGs to be utilized in emergency departments across the country.”

To view the full article, visit https://ibn.fm/sK5gF

About Brain Scientific Inc.

Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• GBM is diagnosed in more than 13,000 people each year in the US, with only a 12–18-month life expectancy
• Potentially pivotal Phase 2 trial of Berubicin is scheduled to commence around the end of Q1 2021
• The company is continuing its pre-clinical work on WP1244 during 2021 and 2022
• CNS Pharmaceuticals participated in two virtual conferences during March, spreading awareness about Berubicin and the GBM indicator

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system, recently announced multiple value-driving milestones for its lead drug candidate Berubicin, a novel therapy targeting glioblastoma multiforme (“GBM”), as well as for its other drug candidate, WP1244, which targets several types of cancer (https://ibn.fm/y1XfB).

Glioblastoma Multiforme (“GBM”) is one of the most aggressive and deadly treatment-resistant cancers of the brain. GBM can affect a patient’s cognition, mood, behavior, and organ function. After diagnosis, the average life expectancy is 12-18 months resulting in close to 10,000 deaths annually in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, this morning announced that it was featured in a NetworkNewsAudio production highlighting the company’s recent news that it has received European approval for its SARS-CoV-2 (COVID-19) RT-PCR test system (Covid-ID Lab). “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” XPhyto CEO and Director Hugh Rogers stated in the original press release. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies and hospitality settings.”

To listen to the NetworkNewsAudio production, visit https://ibn.fm/X4zUI

To view the full press release, visit https://ibn.fm/kvh7E

About XPhyto Therapeutics Corp.

XPhyto Therapeutics Corp. is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Convergence of AI, big data and biology allows Helomics to test drugs on living tumor tissue rather than artificial systems
• Helomics model evaluates multiple measurements in powerful multi-omics approach to cancer research
• Knowledge encapsulated by Helomics AI is “gold dust,” says chief innovation officer

Data, AI and biology come together at Helomics in a way that promises exciting things for the future, according to  Mark Collins, PhD and chief technical officer at the company, which is a subsidiary of Predictive Oncology (NASDAQ: POAI) (https://ibn.fm/ms1hL). Collins was a guest speaker on a DojoLIVE! podcast titled “Can We Cure Cancer with Artificial Intelligence?” where he discussed what Helomics is bringing to the table in the field of cancer research.

“At Helomics, we have a nice convergence of data that we’ve gathered from testing live tumors, tumors outside the patient body, on drugs, standard of care drugs, normal drugs that you might get if you were diagnosed with cancer,” he said…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RYAH Group, a company developing proprietary technology supporting a data-driven approach to health care, appears ready to respond to strict data security requirements. This is an important distinction in an era where the use of telehealth solutions is exploding while securing the integrity of patient information remains critical. The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) is U.S. legislation surrounding requirements for medical providers to integrate privacy and security provisions to safeguard their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain and it is. Therefore, it is critical for health care providers to utilize secure, HIPAA-compliant digital infrastructure to protect both themselves and patients at risk. “As a company focused on the use of health devices, RYAH and its business model is founded on data and data management,” reads a recent article discussing the company’s positioning. “RYAH leverages HIPAA-compliant medical data, fueling complex artificial intelligence algorithms to empower personalized treatment plans based on collective information.”

To view the full article, visit https://ibn.fm/cPuE7

RYAH Group Inc.

RYAH Group is a leader in digital health care analytics and technology. By creating a suite of dose-measuring, IoT devices that capture data from seed to consumption, RYAH is positioned to unearth breakthrough discoveries capable of reshaping the understanding of plant-based medicine. For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Bladder cancer is the 6th most prevalent cancer in the United States and a problem worldwide
• Bladder cancer is more common in men than women at a 4:1 ratio
• Bladder cancer treatment has the highest cost per patient over the course of a lifetime because of its greater than 50% recurrence rate
• Surgeons, including urologists at the University of Washington, have adopted a solution that uses blue light and a contrast agent to better visualize bladder tumors and has been shown to be more successful and reduce costs
• Imagin Medical has taken this solution one step further by developing the i/Blue Imaging System(TM)
• Imagin’s patented technology is expected to be completed next year, after final manufacturing and FDA approval has been received

Urologists at the University of Washington’s research school of medicine in Seattle discussed a blue light cystoscopy system they use that allows “surgeons to better identify non-muscle-invasive bladder cancer,” and improve resection without leaving cells behind to cause recurrence (https://ibn.fm/sdSC9).

This tool will allow us to do better resections and hopefully improve bladder cancer survival,” UW urology professor Dr. Jonathan Wright stated in a…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Researchers from the Royal College of Surgeons in Ireland have found another way to halt excessive inflammation. The method works by regulating a particular type of white blood cells that are crucial for the immune system in the human body. The researchers’ findings could potentially protect an individual’s body from the unhampered damage that is brought about by inflammatory ailments.

The study, conducted by researchers at the University of Medicine and Health Sciences, Royal College of Surgeons in Ireland (“RCSI”), was reported…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group Inc. are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed proprietary technology that solves the issues associated with existing cystoscopies. “White light images show the full landscape of the bladder but do not effectively highlight cancer,” reads an article about the benefits of the i/Blue Imaging(TM) System, Imagin Medical’s proprietary technology. “A promising new modality, blue light cystoscopy, uses blue-filtered white light to detect flat tumors and cancerous cells not seen with white light. However, surgeons can’t operate using blue light images. The blue images aren’t in real-time, orientation in the bladder is easily lost, and the surgeon must manually switch from white to blue cystoscopy and back again. The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies. By combining the white and blue light with an FDA-approved imaging agent, the i/Blue System displays side-by-side images in real-time, without the necessity to switch back and forth between the two images.”

To view the full article, visit https://ibn.fm/HZBkz

About Imagin Medical

Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. For more information about the company, visit www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 was the selection of five U.S. clinical sites for the enrollment of patients for the company’s upcoming phase 2B trial; exclusive licensing agreements with Elion Oncology Inc. and Yuhan Corporation; the appointment of new board and executive team members; and the closing of an underwritten public offering that resulted in $17.1 million. The update also noted that the company anticipated seeing the first patients in its phase 1B clinical study and its phase 2 study dosed in the first half of 2021. Processa Pharmaceuticals held a March 25 conference call reviewing the report; a reply of that call can be obtained by dialing toll-free 877-481-4010 for domestic callers and 919-882-2331 for international callers; the passcode for either call is 40452. “2020 was a transformational year for our company,” said Processa CEO and chair Dr. David Young in the press release. “We in-licensed three exciting programs with potential markets exceeding $1 billion for each drug, improved our balance sheet, strengthened our management team and board, uplisted to Nasdaq, and prepared the foundation for successful execution for our three clinical-stage programs. I am delighted to report that we anticipate the first patients to be dosed with PCS6422 and PCS499 in the second quarter of 2021 with interim data for PCS6422 near the end of Q3 and for PCS499 in the first quarter of 2022.”

To view the full press release, visit https://ibn.fm/KJwtO

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. PCSA’s active clinical pipeline programs include PCS6422 (“PCS6422”) (metastatic colorectal cancer and breast cancer), PCS499 (“PCS499”) (ulcerative Necrobiosis Lipoidica) and PCS12852 (“PCS12852”) (gastroparesis). The markets of each indication are in excess of $1 billion each. The members of the Processa development team have been involved with more than 30 FDA drug approvals, including drug products targeted to orphan disease conditions, and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), reported is financial and operational results for the fourth quarter and fiscal year ending Dec. 31, 2020. The company also held a conference call on March 25, 2021, to discuss the new report. High on the list of significant achievements for the company was a full-year revenue increase of 15%; revenue for 2020 was $13.1 million compared to $11.4 million in 2019. Gross profit and margin was up for both the fourth quarter and fiscal year; the report noted that Vivos also completed a $21.6 million initial public offering in December 2020. Other highlights for the company included the commercial launch of AireO2, a new patient-management software technology, and VivoScore(TM), a comprehensive home sleep test. In addition, the company submitted an FDA 510(k) application for the Vivos mmRNA oral appliance(R). “Successfully introducing a disruptive technology like ours takes a passionate mission-driven team, sufficient capital resources and a little time to execute,” said Vivos chair and CEO Kirk Huntsman in the press release. “Last December, we took a huge step forward with the completion of our IPO, which provided the financial resources to execute our go-to-market strategy. Despite a global pandemic that closed dental offices across the U.S. and Canada for extended periods of time, our company still produced strong 2020 revenue results. . . . We remain fiercely committed to establishing revenue opportunities from complimentary technologies and services.”

To view the full press release, visit https://ibn.fm/M2PZy

About Vivos Therapeutics  Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective, nonsurgical, noninvasive, nonpharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in more than 18,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information about this company, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Vanderbilt University Medical Center (“VUMC”) was recently awarded a $3.7 million, two-year contract by the United States Centers for Disease Control (“CDC”), to discover the bacterial and genetic factors that may grow the risk for critical illness and death from the coronavirus.

The investigation conducted by the center will find out how the severity of the coronavirus may be influenced by respiratory microbiome, which is the bacteria…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that the Wroclaw, Poland-based Lower Silesian Medical Chamber Ethics Committee gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), the company’s sublicensee in Europe and Asia for its lead drug candidate, Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol. The protocol will be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”). This new development set the wheels in motion for the eventual approval of WPD’s studies — a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial. “WPD plans to start the Phase 2 trial in the first half of 2021 and the Phase 1 trial later in 2021,” reads a recent article discussing continued advancement of Berubicin. “This will bring the total number of Berubicin clinical trials to be started in 2021 to three as CNSP will also conduct its Phase 2 trial. CNSP’s Phase 2 trial will evaluate the efficiency and safety of Berubicin as a treatment for adults with GBM who have failed first-line therapy.” Berubicin is CNSP’s novel anthracycline (chemotherapy drug). It is notably unique from other anthracyclines, which have never been used to treat primary or metastatic brain cancers because they did not have demonstrated ability to cross the blood-brain barrier to achieve significant levels of activity in the brain. However, it appears that Berubicin can cross the barrier based on limited clinical data.

To view the full article, visit https://ibn.fm/qmM5Q

About CNS Pharmaceuticals Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Kaival Brands Innovations Group (KAVL), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, has noted recent news from China outlining increased supervision over the e-cigarette category. KAVL, which is the exclusive global distributor of all products manufactured by Bidi Vapor LLC, welcomes the news, particularly as it pertains the BIDI(R) Stick disposable electronic nicotine delivery system (“ENDS”). The company noted that the expanding government regulations align with Kaival Brands’ dedicated and thorough efforts to maintain standards of compliance and quality. Kaival Brands and Bidi Vapor observed that the additional supervision of e-cigarette manufacturing should help raise standards for the devices worldwide. “Creating high-quality, viable alternatives for adult smokers aged 21 and over is a difficult and expensive task,” said Kaival Brands president and CEO Niraj Patel in the press release. “It’s not for the faint of heart, but for us, it’s a matter of integrity and our commitment to quality. . . . The Chinese government’s decisions will have no effect on Bidi Vapor or Kaival Brands and their respective operations, as each company has always been in full compliance with all U.S. requirements and regulations.”

To view the full press release, visit https://ibn.fm/8jUEl

Kaival Brands Innovations Group Inc.

Kaival Brands is a company focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. The company’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. Kaival Brands is the exclusive global distributor of all products manufactured by Bidi Vapor. For more information about the company, visit www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Healthy Extracts (OTCQB: HYEX), a leading developer and manufacturer of heart health, brain health and supplementary technologies, reported a revenue increase of 71% from $748,377 in 2019 to $1,276,559 over the 12 months ending December 31, 2020. The company attributes this growth to the transition to its new business selling health nutrition products, which positions HYEX for opportunity in the booming plant-based foods and products industry projected to reach $74.2 billion in 2027. “We changed our name from Grey Cloak Tech Inc. to Healthy Extracts Inc. to more accurately reflect our business,” a recent article quotes Kevin Duke Pitts, director, president and CEO of HYEX, as stated in the company’s 2020 annual report filed with the SEC on form 10-K. “The name Healthy Extracts Inc. was an important step in aligning our corporate structure and goals with our proprietary products.”

To view the full article, visit https://ibn.fm/Bsn7V

About Healthy Extracts Inc.

Healthy Extracts, through its two subsidiaries, BergaMet NA and Ultimate Brain Nutrients (“UBN”), is engaged in proprietary research and development of natural plant-based formulations, as well as sales and distribution of natural-ingredient cardiovascular and neuro products. For more information about the company, visit www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), which recently received European approval for its COVID-19 rapid and portable test system, has set out to increase its portfolio of tests for different diseases to help fight the current and potential pandemics. XPhyto has partnered with Germany’s 3a-diagnostics GmbH for this, according to an article on the company’s recent announcements. “The company is also working with 3a to develop a portfolio of oral biosensor screening tests that detect bacterial and viral infectious diseases ranging from influenza A to group A strep, as well as focusing on other potential pandemic biosensor tech efforts to combat the spread of the swine flu (‘H1N1′) and avian flu (‘H5N1’) viruses. The company states it is planning to launch its first biosensor product commercially during the latter half of 2021. The biosensor tests will be additions to XPhyto’s portfolio.”

To view the full article, visit https://ibn.fm/oC9EC

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about the company, visit www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that it will present at the Spring 2021 Oncology Investor Conference taking place virtually March 29 – April 2, 2021. According to the update, Genprex’s president and CEO, Rodney Varner, will deliver a virtual company overview that includes GNPX’s novel gene therapies for non-small cell lung cancer and diabetes. Varner’s presentation is scheduled to begin at 2 p.m. Eastern Time on Monday, March 29, and he will be available for one-on-one meetings with investors throughout the conference. Genprex invites investors to register at https://ibn.fm/0Y1gF and join the webcast presentation.

To view the full press release, visit https://ibn.fm/ETMhJ

About Genprex Inc.

Genprex is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The company’s lead product candidate, “REQORSA(TM)” (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (“NSCLC”). REQORSA has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. REQORSA has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for REQORSA for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso(R)) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, visit the company’s web site at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its balance sheet. A highlight mentioned in the letter was that the company had reduced its debt from $5 million to $316,000. Woody also reported that the company had converted $3 million in preferred equity to equity. In the letter, Woody also noted that the company had added two new members to its board of directors and was in the process of adding two additional independent directors to its board, which would bring ATNF in compliance with NASDAQ’s continued listing requirements. The letter also highlighted 180 Life Sciences exciting pipeline, including its three clinical programs: Early Dupuytren’s contracture, a fibrotic disease of the hand; frozen shoulder; and post-operative cognitive delirium disorder and dysfunction, a major unmet clinical need occurring in the elderly patient population. “At 180 Life Sciences, we continue to move forward on all fronts. Including efforts to increase visibility for our team and its mission. We are proactively working on telling our story through a steady flow of participation in investor conferences, thought leadership opportunities through earned media, and continued amplification through social media channels,” wrote ATNF CEO James Woody in the letter. “It is important to note that our business model itself is unique for a biotech company. Almost all our clinical studies to date have been funded in full through grants. While ultimately, we intend to fund some studies internally, we anticipate our operating expenses will remain low relative to our peers. There are many advantages of doing clinical development mostly with academic leaders, both in cost, efficiency and credibility.”

To view the full press release, visit https://ibn.fm/upPT4

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at http://ibn.fm/ATNF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A study led by researchers from University College London has found that individuals who suffered head injuries when they were aged 50-something or below attained below-average scores on cognitive tests administered when they were age 70.

The study’s findings, which were reported in the “Annals of Clinical and Translational Neurology,” found that while head injuries were not found to contribute to Alzheimer’s disease brain damage characteristics, they did make individuals more susceptible…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

New research conducted that focuses on military veterans has found that good sleep plays an important role in helping heal traumatic brain injuries. The study utilized a novel technique that was developed at the Oregon Health and Science University. Researchers assessed the expansion of perivascular spaces around the brain’s blood vessels using MRIs, reporting that these spaces enlarge as an individual continues ageing and are usually linked to the onset of dementia. The researchers found that of the veterans who participated in the research, those who didn’t sleep well had more post-concussive symptoms and indications of enlarged spaces.

Juan Piantino, an assistant professor of pediatrics with a focus on neurology from the OHSU School of Medicine, was the lead author of the study; he stated that this research has huge consequences for civilians as well as the armed forces, explaining that the research suggests that sleep played a critical role in clearing waste in an individual’s brain following a traumatic brain injury, adding that if an individual…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Imagin Medical believes the i/Blue System can revolutionize the current standard of care for bladder cancer patients by improving cancer visualization for removal, and potentially lowering recurrence rates
• Imagin Medical is leveraging the significant expertise in optics, electronics, software, and mechanical design of FDA-registered contract manufacturer, Lighthouse Imaging, to implement the final stage of the i/Blue(TM) Imaging System
• Lighthouse’s manufacturing program remains on track for product commercialization in 2022

Surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) is continuing progress with the commercial-stage manufacturing  of its patented i/Blue Imaging System, an innovative technology that the company believes will revolutionize the way surgeons visualize the bladder and identify cancers during minimally invasive surgery. The company has been working with contract manufacturer, Lighthouse Imaging, to complete the system for commercialization. In a company press release, Imagin Medical’s President and CEO, Jim Hutchens, said the COVID-19 pandemic impacted the company’s production timeline by approximately nine months, which moved product completion into… Read More>> NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF About BioMedWire BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information, please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork.

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, Brad Amman, and Investor Relations Officer, Ed Loew, will be presenting at the event with their presentation scheduled to begin at 11:40 a.m. EST on Thursday, March 25, 2021. Investors interested in joining the Vivos presentation can register for a free spectator pass at https://ibn.fm/jQW0J.

To view the full press release, visit https://ibn.fm/wFANb

About Vivos Therapeutics Inc.

Vivos Therapeutics is a medical technology company focused on developing and commercializing innovative treatments for adult patients suffering from sleep-disordered breathing, including obstructive sleep apnea (“OSA”). The Vivos treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. Vivos believes that its Vivos System technology represents the first clinically effective non-surgical, non-invasive, non-pharmaceutical and cost-effective solution for people with mild-to-moderate OSA. Vivos oral appliances have proven effective in over 15,000 patients treated worldwide by more than 1,200 trained dentists. Combining technologies and protocols that alter the size, shape and position of the tissues of a patient’s upper airway, the Vivos System opens airway space and can eliminate or significantly reduce symptoms and conditions associated with mild-to-moderate OSA. The Vivos System has been shown to significantly lower Apnea Hypopnea Index scores and improve other conditions associated with OSA. The Vivos Integrated Practice (“VIP”) program offers dentists training and other value-added services in connection with using the Vivos System. For more information, visit www.VivosLife.com.

NOTE TO INVESTORS: The latest news and updates relating to VVOS are available in the company’s newsroom at http://ibn.fm/VVOS

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as CEO. Engle has more than two decades of impressive experience in the biotech and health-care industries. In his various roles as president, CEO, director, chairman of the board, CFO, senior vice president and more, he has gained invaluable expertise and insight into driving sales, unveiling new products and turning companies around. He has worked in C-level positions Thermogenesis, Dey LP and Allergan; he also founded and led his own consulting practice. Engle was named to POAI’s Board of Directors in October 2016 and was appointed chair in January 2020. “I believe that Predictive Oncology is positioned for success, and I look forward to working with our team to achieve its strategic short- and long-term objectives,” said new POAI CEO J. Melville (“Mel”) Engle in the press release. “I am excited about the prospects of making a positive impact in enhancing the value for our stakeholders.”

To view the full press release, visit https://ibn.fm/wc4VA

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA (“DNA/RNA”) and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood and irrigation fluid, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its fourth-quarter financial report as well as to provide a drug-development update. The conference call and life webcast will be available to any participants dialing or logging in. Interested parties can dial 877-545-0320 in the United States or 973-528-0016 for international calls; the entry code is the same for both: 805295. A replay of the call will be available as well. To access that, interested parties can dial 877-481-4010 in the United States or 919-882-2331 for international calls; the entry code is the same for both: 40452.

To view the live webcast, visit https://ibn.fm/55Pt8

To view the full press release, visit https://ibn.fm/7Fkf4

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. PCSA’s active clinical pipeline programs include PCS6422 (“PCS6422”) (metastatic colorectal cancer and breast cancer), PCS499 (“PCS499”) (ulcerative Necrobiosis Lipoidica) and PCS12852 (“PCS12852”) (gastroparesis). The markets of each indication are in excess of $1 billion each. The members of the Processa development team have been involved with more than 30 FDA drug approvals, including drug products targeted to orphan disease conditions, and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are direct GABA-A receptor positive modulators. The objective is for PH94B to displace these and other benzodiazepines, which are widely used but addictive, as a viable treatment for social anxiety disorder (“SAD”) and other anxiety disorders and phobias. SAD is the third most common mental health disorder among Americans, and recent studies indicate that an estimated 20 million individuals suffer with the debilitating disorder. “Given the FDA’s recent Drug Safety Communication that outlined and highlighted the safety risks associated with benzodiazepine use, the implications resulting from this study are significant,” said VistaGen chief medical officer Mark Smith, M.D., Ph.D., in the press release. “PH94B may have the potential to displace benzodiazepines altogether and become the safer alternative to help the millions of Americans suffering from anxiety with limited options for safe, effective treatment options. These existing treatments can actually hurt instead of help. We look forward to launching our Phase 3 clinical development program for PH94B next quarter and continuing to push forward in our mission to get it into the hands of those in need as soon as possible.”

To view the full press release, visit https://ibn.fm/guWqd

About VistaGen Therapeutics Inc.

VistaGen is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information about the company, please visit www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

A new study that was conducted to get to the bottom of whether the coronavirus causes heart issues where there are none, or whether individuals who already have heart problems are more prone to the virus, found that individuals with pre-existing heart issues appeared to have a higher risk of contracting the coronavirus.

Zahra Raisi-Estabragh, the lead researcher of the study, explained that the team found that poorer heart function and structure was associated with an increased risk of getting the coronavirus. This, she said, was important because other studies had proposed that the coronavirus…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to Predictive Oncology (NASDAQ: POAI) are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial,” said James Sapirstein, president, CEO and chairman of AzurRx. “Based on the very encouraging clinical results to date, we believe that the combination therapy has significant potential to help the 25-30% of refractory cystic fibrosis patients with severe EPI who are unable to achieve adequate nutrition using PERT alone. Adding a small dose of MS1819 can help these patients meet their nutritional needs, reduce the debilitating symptoms of EPI and improve their overall quality of life, with an increased safety profile.”

To view the full press release, visit https://ibn.fm/s3298

About AzurRx BioPharma Inc.

AzurRx BioPharma is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, currently in two Phase 2 clinical trials. AzurRx is launching two clinical programs in 2021 using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, FW-420, for grade 1 immune checkpoint inhibitor colitis and diarrhea in oncology patients and FW-1022, for COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• New York City ramps up rapid testing efforts, opens 11 rapid-testing sites; others to follow
• Mayor notes that low-cost, rapid-testing made available to public is key to accelerating economy’s re-opening
• UME offers rapid -testing kits, provides products and services essential for curbing pandemic and jumpstarting economic recovery

United Medical Equipment Business Solutions Network (“UME”), a trusted supplier of COVID-19 antigen and antibody testing kits, is offering a key product that could impede the spread of the virus and speed up economic recovery. A top U.S. testing official announced a scale-up in the country’s diagnostic efforts, touting both health and economic benefits of rapid testing outside the lab. New York City is wasting no time to leverage the power of this low-cost, high-impact option as the city has announced the launch of its Forward Rapid-Test Program (https://ibn.fm/RmtcD).

The program will make low-cost rapid testing available to the broader public to support economic recovery by enabling businesses to more safely re-open. The city has initially announced that 11 sites will open with the capacity to conduct more than 5,000 tests every day. Additional locations are…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

RYAH Group, a leading digital health care analytics and technology company, has developed a technology that collects and analyzes patient data, creating an anonymous database that, when coupled with AI, will guide the future of medical treatments. With the technology, “patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time,” reads an article on the developments. “The patient controls the process, and the instruments that collect digital data remain anonymous. When patient feedback is optimized, medical trials and studies can move into remote solution zones… RYAH is focused on expanding the understanding of proprietary technology that supports a data-driven approach to positively impact patients’ future treatment for various medical conditions. By coupling an anonymous database with AI, the company has created a cloud of stored data to help with the R&D of future medical treatments. RYAH is actively making digital transformation in the lab a reality, paving the way forward for a medical future with remote solutions.”

To view the full article, visit https://ibn.fm/NdYmQ

RYAH Group Inc.

RYAH Group is a leader in digital health care analytics and technology. By creating a suite of dose-measuring, IoT devices that capture data from seed to consumption, RYAH is positioned to unearth breakthrough discoveries capable of reshaping the understanding of plant-based medicine. For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Fluid management systems, accessories market forecast at 13.6% CAGR to $16.1 billion by 2025
• Skyline Medical’s STREAMWAY(R) System disrupts today’s standard of manually moving waste fluid for disposal
• STREAMWAY Systems eliminates waste transport, disposal costs, equipment relocation and risk of exposure to potentially contaminated fluids.

For every healthcare facility, particularly hospitals and surgical centers, disposal of waste fluids presents a unique set of challenges related not only to regulations but also staff safety. Improper disposal can result in hefty fines and possibly risk exposure to infectious fluids. For the most part, the legacy technology of draining fluid into a canister is the hospital standard, making the industry ripe for innovation. After a year of the coronavirus pandemic leading to postponements of countless elective surgeries, Skyline Medical, a division of Predictive Oncology (NASDAQ: POAI), looks to have well-timed renewing development of its new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management.

According to analysts at MarketsandMarkets, the fluid management systems and accessories market is projected to reach $16.1 billion in 2025 from $8.5 billion in 2020, expanding at a 13.6% compound annual growth rate…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

United Medical Equipment (“UME,” “UMEBSNI”) continues to move quickly to address the unique testing needs created by the ongoing global pandemic. UMEBSNI is a trusted supplier of FDA-approved COVID-19 rapid antigen test kits as part of its efforts to provide essential services during the epidemic. The company’s COVID-19 IgG/IgM Rapid Test Cassette detects coronavirus antibodies that appear in the bloodstream of individuals infected with the virus within 10 minutes. In addition, the test can also indicate whether a person has protection against the coronavirus. A recent article discussing this reads, “Other features of the test include the following: FDA Emergency Use Authorization (‘EUA’); Small sample sizes; works with whole blood, plasma and serum samples; Shelf life of up to 24 months from date of manufacture; Stored at room temperature or refrigerated (2 to 30°C); Available in quantities of 25. The kits are for medical professional use only and are approved for use in CLIA moderate- or high-complexity settings. In addition, verification of use case prior to shipping is mandatory.” To view the full article, visit https://ibn.fm/ZiWn5 About United Medical Equipment Business Solutions Network Inc. United Medical Equipment Business Solutions Network offers reliable resources and solutions that are designed to meet the ever-changing needs of an aging population, which includes seniors and veterans. The company’s owners and founders bring decades of combined business, military and cardiovascular critical care nursing experience. United Medical Equipment understands the needs and concerns of the aging population, including veterans and their families, and offers the support, solutions and reliable information critical in making informed decisions. UMEs’ mission is to provide guidance for caregivers, veterans, the aging population and medical community through its medication management and telehealth applications by providing reliable resources, products and support services designed to meet unique needs. For more information, visit the company’s website at www.UnitedMedSolutions.com. NOTE TO INVESTORS: The latest news and updates relating to UME are available in the company’s newsroom at https://ibn.fm/UnitedMed About BioMedWire BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge. To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only) For more information please visit https://www.BioMedWire.com Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer BioMedWire (BMW) San Francisco, California www.BioMedWire.com 415.949.5050 Office [email protected] BioMedWire is part of the InvestorBrandNetwork

New research has found that maternal exercise may allow mothers to considerably decrease the chances of their children developing metabolic diseases, such as diabetes, as they grow older. The study, which was conducted on lab mice, discovered that exercising during pregnancy hindered the transmission of metabolic ailments from an obese father or mother to the child. The researchers reported that if these findings remain unchanged in humans, it could significantly help pregnant women ensure that their children lived healthy lives.

Leading exercise expert from the University of Virginia School of Medicine Zhen Yan, who is also a researcher, explained that the majority of the chronic illnesses individuals suffer from currently have a fetal origin. This, Yan said, indicated that the poor health…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Bladder cancer is the fourth most common cancer in men andexpected to cause more than 17,000 deaths in the United States this year
• Imagin Medical is advancing its patented bladder cancer visualization technology toward commercialization and FDA approval, expecting the technology to revolutionize blue light cystoscopy procedures and improve patient outcomes in the process
• Imagin is funding its efforts with $2.165 million raised towards its convertible note offering
• Rollout of the company’s manufacturing process was delayed about nine months as a result of the COVID-19 pandemic.but Imagin and its production partner remain on its revised schedule
• The company expects to expand its product line once the bladder cancer technology rolls out, adapting its IP for use with other contrast dyes so the technology can be used in additional endoscopic procedures

Imagin Medical (CSE: IME) (OTCQB: IMEXF) announced on March 16 that its product development partner, ISO 13485:2016-certified manufacturer, Lighthouse Imaging, is making progress towards commercial-stage manufacturing capability of the novel, state-of-the-art bladder i/Blue Imaging System (TM) for use in bladder cancer visualization procedures.

“Prior to Imagin’s selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System (TM) in October 2020, the Company received multiple fully functional feasibility units from its original design partner, Optel, Inc.,” the news release states…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds for working capital and general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering.

For more information about the company, visit www.BioPathHoldings.com

About Bio-Path Holdings Inc.

Bio-Path Holdings is a biotechnology company developing DNAbilize(R), a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (“BP1001,” targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by “BP1002,” targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

The coronavirus pandemic has affected various sectors of the economy, with the health-care sector being the most overwhelmed. The public health and economic burdens that the pandemic has caused call for us to reevaluate our approach to developing new therapies and vaccines. In an attempt to gather what can be applied to research and development in the future, we look at a few useful lessons that health-care researchers can gain from this pandemic experience.

At the onset of the pandemic, there was a lot about the coronavirus that was unknown. We observed many organizations working together to learn more about this highly infectious disease, which resulted in a lot of meaningful progress being made. Partnering up to develop therapies…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Company reports positive clinical results from HERHEART(TM) and Fuel4Thought(TM), produced by subsidiaries BergaMet North America and Ultimate Brain Nutrients
• Purchase agreement with Xymogen(R) for BergaMet North America’s Citrus Bergamot SuperFruit(TM) expected to generate significant revenue and distribution opportunities nationwide
• The global market for botanical and plant-derived drugs was valued at $29.4 billion in 2017 and is expected to reach $39.6 billion by 2022
• Healthy Extracts is nearly debt-free with minimal overhead costs

Through a growing portfolio of wholly owned subsidiaries, Healthy Extracts (OTCQB: HYEX) (formerly Grey Cloak Tech) is engaged in proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. Through its unique assets and operations of subsidiaries BergaMet North America and Ultimate Brain Nutrients (“UBN”), the company aims to offer better lifestyle opportunities while advancing its market position in the health industry.

The company has recently announced promising results of clinical studies for two leading products: BergaMet North America’s HERHEART(TM) and…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to HYEX are available in the company’s newsroom at https://ibn.fm/HYEX

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH (“3a”), has received European approval of its point-of-care SARS-CoV-2 RT-PCR test system, called Covid-ID Lab. Covid-ID Lab is now registered as a commercial in vitro diagnostic (CE-IVD) test in Europe, and plans are in place to launch the product in Europe in April 2021. XPhyto is exploring options with various potential distribution and wholesale partners as well as potential licensees. The test offers high sensitivity, high specificity, and high robustness, with no impact on results from minor changes in process parameters. In addition to detecting COVID-19, specificity of 100% against 19 pathogens of serious respiratory infections was demonstrated on a respiratory verification panel. In testing, the systems showed precision through evaluation of variance of the analysis results due to random deviations, a repeatability/intra-assay precision. “Our test is one of the fastest PCR-based COVID-19 tests currently approved. With a sample collection to result time of 25 minutes, Covid-ID Lab combines the speed of a rapid screening test with the accuracy of a PCR diagnostic,” said XPhyto director and CEO Hugh Rogers in the press release. “Covid-ID Lab is designed for point-of-care testing, particularly in satellite and small-scale labs, such as transportation hubs, borders, care facilities, schools, pharmacies, and hospitality settings.”

To view the full press release, visit https://ibn.fm/M9XIB

About XPhyto Therapeutics Corp.

XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Several economic development figures and public officials recently established a research park to help attract science, technology and biomedical companies to Monroe, Louisiana. The not-for-profit organization launched the Biomedical Research and Innovation Park, which would collaborate with the University of Louisiana-Monroe and would inhabit a proposed facility near the institution’s College of Pharmacy facility.

Monroe’s Dr. Ray Armstrong, who was the lead in the creation of the research park, stated that the park would not only focus on biomedical research but that…

Read More >>

NOTE TO INVESTORS: The latest news and updates relating to United Medical Equipment Business Solutions Network Inc. are available in the company’s newsroom at https://ibn.fm/UnitedMed

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

• Imagin Medical is a surgical company focused on developing its i/Blue(TM) Imaging System, employing patented ultrasensitive imaging technology
• The i/Blue(TM) Imaging System is system compatible; system attaches to most endoscopes
• The company recently closed the second tranche for the amount of US$1,415,500 of the Convertible Note offering

Imagin Medical (CSE: IME) (OTCQB: IMEXF) is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive surgical procedures. Imagin Medical is run by an experienced management team that is preparing their i/Blue(TM) Imaging System for the industry. An FDA approval process is underway.

The company’s patented ultrasensitive imaging product, the i/Blue(TM) Imaging System, based on optics and light sensors, has potential early-stage cancer-detection abilities. The company’s first target for…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In addition, two to three more clinical sites will be selected for the trial, “A Randomized, Double-blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of PCS499 in Treating Ulcerations in Patients who Have Necrobiosis Lipoidica.” “We have selected five U.S. sites to evaluate this groundbreaking new treatment for ulcerative necrobiosis lipoidica, and we expect to add a few more sites in the next few months including sites outside the U.S.,” said Dr. Sian Bigora, chief development officer at Processa. “Unfortunately for patients with ulcerative necrobiosis lipoidica, open ulcers often take years to naturally heal, if they heal at all, and treatments to close the ulcers in these patients do not exist. Fortunately, our preliminary clinical evaluation of PCS499 in the treatment of patients with ulcerative necrobiosis lipoidica suggests that PCS499 may be effective in closing these ulcers within months of starting treatment.”

To view the full press release, visit https://ibn.fm/xwSSr

About Processa Pharmaceuticals Inc.

The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

MRVL Pet Pharmaceuticals(TM), a life sciences and technology company focused on the animal health sector, today announced its entry into an agreement with the Life Sciences division of Altran, a Capgemini company, to provide advisory services on their U.S. FDA clinical trial process for canine and feline cancer and arthritis products. According to the update, renowned veterinary expert Dr. Albert Ahn was appointed as the chief researcher of the clinical trial that launched on Jan. 27, 2021, and is expected to consist of three phases and run until Dec. 30, 2022. Altran’s AVP of Regulatory Affairs, Quality and Compliance, Deborah Cenci, was appointed as clinical trial manager. “Dr. Ahn and I are excited about this groundbreaking and innovative line of global non-invasive therapeutic solutions for companion pets. After 30 years of combined life sciences experience and over 360 Rx Drug approvals and launches, we are extremely confident that MRVL will not only obtain regulatory approval but will also become a global leader in the industry,” Cenci said in the press release. “We feel that MRVL will fulfill an important unmet need in veterinary oncology and arthritis for companion pets, with an initial focus on mass cell tumor for canines and lymphoma cancers for feline pets.”

To view the full press release, visit https://ibn.fm/j6Fge

About MRVL PET Pharmaceuticals(TM) Corp.

MRVL PET Pharmaceuticals is a life sciences and technology company focused on the animal health sector with a primary mission of developing and marketing its companion animal products to the retail and veterinary markets. MRVL is developing products targeting canine and feline cancer and arthritis for CVM/FDA approval as well as launching a nutraceutical formulation for pet immune and joint support. MRVL has entered into an agreement to acquire MRVL Island Ventures Limited (“MRVL Island”), which is expected to close imminently. MRVL Island is the holder of an exclusive license to manufacture, use and sell its proprietary Blue Scorpion venom and Blue Scorpion Peptide CTX throughout North America, Europe and the United Kingdom. For more information, visit www.MRVLPETPharmaceuticals.com

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, recently announced a collaboration with JelikaLite, a company developing Cognilum(TM), a non-invasive wearable photobiomodulation device that is being developed to increase the well-being of children living with autism, through a clinical trial. In the trial, “Transcranial Photobiomodulation for Reducing Autism Symptoms in Children,” brain treatments for children diagnosed with autism would be delivered through Cognilum, while Brain Scientific’s NeuroEEG, a wireless EEG device, will monitor brain activity. The trial is designed to provide researchers and clinicians an opportunity to potentially uncover new treatment options for reducing the symptoms children with autism experience. “We are delighted to begin this collaboration with JelikaLite,” said Brain Scientific’s Director of Marketing, Irina Nazarova. “Our Neuro EEG solutions have a wide range of applications and helping to monitor children with autism to improve their well-being would be an important step towards a wider adoption of affordable and accessible EEG systems like ours.”

To view the full press release, visit https://ibn.fm/ClDKv

About Brain Scientific

Brain Scientific is a commercial-stage health care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

• Brain cancer drug developer CNS Pharmaceuticals is finalizing preparations to begin March enrollment of patients in its potentially pivotal Phase 2 trial evaluating its promising lead candidate, Berubicin, for the overall survival improvement of glioblastoma (“GBM”) patients
• Glioblastomas are a type of brain cancer that have continued to elude effective therapy over the past century of investigation, leaving patients with expectations of approximately 15 months of survivability beyond diagnosis and recurrence after surgical removal
• A GBM patient in a small Phase 1 Berubicin safety trial 15 years ago has remained cancer-free and stable as of last November, a hint of Berubicin’s potential
• CNS Pharmaceuticals’ sublicensee partner, WPD Pharmaceuticals, is similarly preparing to launch a parallel Phase 2 adult GBM trial in Poland this year, and plans to begin a Phase 1 trial for malignant gliomas in pediatric patients by the end of the year

Glioblastoma may not be a household word but during 2020 more than 13,000 new diagnoses of the deadly brain cancer were expected to hit home for Americans, according to the National Brain Tumor Society. The service and research-funding organization reports that glioblastoma, or GBM, was first identified in scientific literature a century ago but that only four drugs and one device to treat GBM have been approved by the U.S. Food and Drug Administration (“FDA”) since then, and that none of the treatments have been able to significantly extend patients’ lives beyond a few extra months (https://ibn.fm/t9l9g). This sad fact holds true regardless of access to the best care in the world – even President Biden’s son Beau passed away from GMB, in 2015.

Texas-based biopharmaceutical company…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork.

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has announced the completion of enrollment for its phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis (“CF”) patients with exocrine pancreatic insufficiency (“EPI”). According to the announcement, the company enrolled 30 CF patients for the study, which is anticipated to return top line data by the end of Q1 2021. The upcoming phase 2b, multicenter study will investigate the safety, tolerability and efficacy of MS1819 in a head-to-head comparison against the current porcine enzyme replacement therapy (“PERT”) standard of care. MS1819 is a recombinant lipase enzyme formulated for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The overarching goal of the company’s MS1918 program is to offer a safe, effective therapy to control EPI and improve upon the current standard of care. MS1819 is a synthetic lipase that does not contain any animal products and offers the potential to significantly reduce the daily number of pills the current standard of care requires. “Completion of enrollment in our Phase 2b OPTION 2 trial is an important milestone in the clinical development of MS1819 as an EPI monotherapy for patients with cystic fibrosis,” said AzurRX president, chairman and CEO James Sapirstein in the press release. “Data from this trial will inform the optimal dose for a potential pivotal Phase 3 study, and we are on target to report topline results from this study at the end of the first quarter of 2021.”

To view the full press release, visit https://ibn.fm/oJ2nP

About AzurRx BioPharma Inc. 

AzurRx BioPharma is a clinical-stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases. The company has a pipeline of three gut-restricted GI assets. The first is MS1819, a recombinant lipase biologic for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis and chronic pancreatitis, with two ongoing phase 2 clinical trials. The other two are clinical-stage therapies using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor: FW-420, for the treatment of grade 1 immune checkpoint inhibitor associated colitis (“ICI-AC”) and diarrhea in oncology patients, and FW-1022, for the treatment of COVID-19 gastrointestinal infections. The company is headquartered in Delray Beach, Florida, with clinical operations in Hayward, California. For more information, visit the company’s website at www.AzurRx.com.

NOTE TO INVESTORS: The latest news and updates relating to AZRX are available in the company’s newsroom at https://ibn.fm/AZRX

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced continued progress towards commercial-stage manufacturing capability with Lighthouse Imaging. Prior to selection of Lighthouse as its contract manufacturer for the i/Blue Imaging System(TM) in October 2020, Imagin received multiple fully functional feasibility units from its original design partner, Optel Inc. Lighthouse’s development program has since focused on further refining the design to support Imagin’s submissions to the U.S. Food and Drug Administration, as well as to ensure final device performance, compliance with all applicable regulatory standards, and optimal manufacturability to meet cost targets and anticipated user demand. “We chose Lighthouse because of its accomplished history of taking innovative products like our i/Blue System and applying its cross-functional expertise in optics, electronics, software and mechanical design to move into commercial manufacturing,” said Imagin’s Director of Engineering and Quality, Mike Vergano. “We have not been disappointed. The Lighthouse team’s work to-date has been exceptional, and we look forward to that continuing.”

To view the full press release, visit https://ibn.fm/uBRbZ

Imagin Medical Inc.
Imagin Medical is a surgical imaging company focused on advancing new methods of visualizing cancer during minimally invasive procedures. The company believes its first product, the i/Blue(TM) Imaging System, with its proprietary optics and light sensors, will greatly increase the efficiency and accuracy of detecting cancer for removal, helping to reduce recurrence rates. The company’s initial focus is bladder cancer. Learn more at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual Conference taking place on March 17-19, 2021, Singh will deliver a corporate presentation and participate in a fireside chat, scheduled to begin at 1 p.m. ET on Friday, March 19. In addition, Singh will deliver a corporate presentation at the Benzinga Biotech Small Cap Conference, which is scheduled for 10:05 a.m. ET on Thursday, March 25. For more information regarding the events, please visit the sponsor conference websites.

To view the full press release, visit https://ibn.fm/ntncx

About VistaGen Therapeutics Inc.

VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork